SAN DIEGO, May 24, 2013 (GLOBE NEWSWIRE) -- Sente, Inc., a privately held cosmeceutical company engaged in the development of differentiated medical skincare products based on glycoproteins, announced today that it has appointed Magda Marquet, Ph.D. to its board of directors, effective immediately. Dr. Marquet is Sente's fourth director and brings additional biotechnology industry operations and management experience to Sente's board of directors.
Dr. Marquet is the founder and co-Chair of Ajinomoto Althea Technologies, and served as its co-President and CEO for ten years. Dr. Marquet is also founder and co-Chair of Althea Dx, a spin-off of Althea Technologies focusing in companion diagnostics development. She is the Chairwoman of BIOCOM and she is on the Board of UCSD Moores Cancer Center. She is currently involved as investor, adviser, and board member in over twenty local San Diego companies. Dr. Marquet has over twenty-five years of experience in the biotechnology industry in the United States and Europe. She was formerly Executive Director of Pharmaceutical Development at Vical Incorporated, where she patented several novel methods for the production of clinical grade DNA for use in gene therapy and DNA vaccines. Prior to joining Vical, Dr. Marquet held management positions at Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. Dr. Marquet holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet was the winner of the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category.
"We are extremely pleased to have Magda join our Board at this important transformational stage of the company's growth and development," said Faheem Hasnain, Chairman of the Board of Directors of Sente, Inc. and CEO of Receptos. "Given Magda's extensive knowledge and understanding of the development and commercialization of pharmaceutical grade products across a wide range of indications, she will be an invaluable addition to the Sente team."
"Sente's approach to developing and commercializing promising medical grade skincare products is very exciting," said Dr. Marquet. "I believe that Sente's differentiated technology and validated dermatological products have significant commercial potential and I look forward to collaborating with the Senté team and Board of Directors to fully harness the power of their glycoprotein based skincare products."
About Senté, Inc.
Senté, Inc. is a privately held cosmeceutical company based in San Diego, California. The company is a recognized leader in the development of innovative and targeted medical skincare products based on glycoproteins. Senté recently launched its first physician dispensed dermatological product, Senté Dermal Repair Cream, which is currently the only cosmeceutical product utilizing heparan sulfate on the market today. Senté is leveraging its expertise in biotechnology to delivering novel products for a variety of dermatological concerns. More information on the company can be found at http://www.sentelabs.com.